Regencell Bioscience (RGC)
Develops standardized traditional Chinese medicine formulas for ADHD and autism spectrum disorder.
Something off on this page? Send us feedback.
Develops standardized traditional Chinese medicine formula candidates for ADHD and autism spectrum disorder from a Hong Kong research base. The pre-revenue program has no product in regulatory approval or commercialization and depends on an exclusive formula partnership with the founder's father.
Develops traditional Chinese medicine formula candidates for attention-deficit/hyperactivity disorder and autism spectrum disorder. The program converts personalized prescriptions into standardized liquid formulas adjusted for mild, moderate, and severe conditions.
Research and operations are based in Hong Kong. Development has centered on small, uncontrolled or non-blinded company-run studies, while no formula has entered regulatory approval or commercialization and the business has generated no revenue since inception.
Formula rights and development depend on an exclusive partnership with practitioner Sik-Kee Au, the founder and chief executive's father. Founder Yat-Gai Au retains controlling ownership, and a disclosed U.S. Justice Department investigation covers trading in the shares and other operational, financial, and accounting matters.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $2.4M · Total debt $386.3K · Total assets $3.0M · Shareholders' equity $1.2M
- Revenue
- $0
- Operating income
- −$5.3M
- Net income
- −$5.3M
No dividends on record.
| Institutions37 holders · as of Mar 31, 2026 | 0.13% | 647.2K ADS | |
| Insiders3 holders · as of Mar 18, 2026 | 88.62% | 439.08M ADS | |
| Otherremainder | 11.25% | 55.75M ADS |
495.47M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Jun 2025 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Yat-Gai AuInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 88.38% | 437.90M ordinary | Form 4filed Mar 18, 2026 ↗ |
Margaret Hoor Han LoInsiderdirector | 0.12% | 604,050 ordinary | Form 4filed Mar 18, 2026 ↗ |
Yat-Pui AuInsiderofficer: Chief Business Officer | 0.12% | 581,514 ordinary | Form 4filed Mar 18, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.08% | 415,569 ADS | 13Fas of Mar 31, 2026 |
Marex Group PLCInstitution | 0.01% | 31,600 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Takeda (ADR)
Marketed ADHD medicines versus standardized TCM formulas in development
- Supernus Pharmaceuticals
Approved Qelbree overlaps with RGC’s development-stage ADHD program
- Aytu BioPharma
FDA-approved stimulant tablets overlap with investigational ADHD formulas
- Cingulate
Develops an investigational once-daily ADHD stimulant
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Regencell Bioscience | $6.39 | +1.91% | $3.13B | — | — | — | — |
| Takeda (ADR) | $18.64 | +1.08% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Supernus Pharmaceuticals | $43.90 | −0.30% | $2.56B | — | 15.2 | 3.1 | +32.4% |
| Aytu BioPharma | $2.30 | +2.22% | $24.5M | — | — | 0.4 | −32.7% |
| Cingulate | $5.10 | −1.16% | $69.4M | — | — | — | — |
| Median | 51.2 | 35.9 | 2.0 | +5.8% |